View More Recent Stories

Sep 25, 2024 06:38AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Sep 24, 2024 10:47AM Increasing unusual call option volume: SMAR MCHI TME ASHR TIGR BBIO POET ROIV CAPR
Sep 24, 2024 08:01AM Capricor Therapeutics (CAPR) Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Sep 23, 2024 01:00PM Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR), 'Accelerated Approval May Be In The Cards'
Sep 23, 2024 09:25AM Capricor Therapeutics (CAPR) to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
Sep 18, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Sep 17, 2024 04:02PM Capricor Therapeutics (CAPR) PT Raised to $15 at Oppenheimer
Sep 17, 2024 09:17AM Capricor Therapeutics (CAPR) Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Aug 7, 2024 04:20PM Capricor Therapeutics (CAPR) Tops Q2 EPS by 1c
Jul 2, 2024 06:40AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Jun 25, 2024 08:32AM Capricor Therapeutics (CAPR) announces FDA has scheduled Pre-BLA meeting for deramiocel to treat DMD
Jun 14, 2024 04:43PM Capricor Therapeutics (CAPR) Files $150M Mixed Shelf
Jun 11, 2024 09:25AM Capricor Therapeutics (CAPR) Announces Positive Type-B Meeting with FDA for CAP-1002 Program
View More Recent Stories